New York, June 21, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Amlodipine Besylate Market 2022-2026" - https://www ...
Yesterday’s Federal Court decision invalidating Pfizer’s Norvasc (amlodipine besylate) could give an early boost to Novartis’ Exforge. “Besides the generic companies that will be launching their ...
Pfizer Wins Challenge to Norvasc Patent by Mylan Laboratories NEW YORK, Feb. 27 -- Pfizer Inc said today that a federal court in the Western District of Pennsylvania (Pittsburgh) has upheld the ...
A federal court jury in the Eastern District of Virginia ruled unanimously that Pfizer did not infringe Synthon IP’s US patent covering a process for making amlodipine, the active ingredient in the ...
Nov. 11, 2005 — The U.S. Food and Drug Administration (FDA) has approved first-time generic formulations of glimepiride 1-, 2-, and 4-mg tablets and first-time doses of 3-, 6-, and 8-mg tablets for ...
Shares of US generic drugmaker Mylan Laboratories jumped 5.3% to $20.40 on October 4, overshooting the firm’s 52-week high on the news that final clearance from the US Food and Drug Administration to ...
New York, NY (Jan. 31)-Pfizer, Inc. scored a victory over Synthon IP in a patent infringement lawsuit over the manufacturing process for ?Norvasc? (amlodipine). According to Pfizer, the federal ...
Pittsburgh, PA-The US Food and Drug Administration has given the green light to Mylan Pharmaceuticals to market a generic version of the popular blood-pressure-lowering agent amlodipine (Norvasc, ...
Co announces it launched Amlodipine Besylate Tablets, 2.5 mg, 5 mg and 10 mg. Amlodipine Besylate Tablets are the generic version of Pfizer's Norvasc Tablets, which had U.S. sales of approximately ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results